Shots:

• The company reported in its Q1 results that the US FDA has accepted its NDA of (mRNA-1273) and allow it to initiate P-II study evaluating the therapy in 600 patients divided into two cohorts- aged 18-55yrs. and another of people aged 55+ yrs.- expected to begin shortly
• Moderna is finalizing the protocol for P-III study of mRNA-1273 and is expected to initiate the clinical study in early summer of 2020
• With the focus of initiating the mRNA-1273 Phase III study early this summer- Moderna is now preparing to potentially have its first approved BLA as early as 2021. Additionally- the company highlighted its deal with Lonza to manufacture up to 1B doses of mRNA-1273/yr.

Click here to­ read full press release/ article | Ref: Moderna | Image: Moderna

Related News: Moderna Signs a Ten-Year Worldwide Agreement with Lonza to Manufacture mRNA-1273 Against COVID-19